← Back to Screener
Prime Medicine, Inc. Common Stock (PRME)
Price$3.67
Favorite Metrics
Price vs S&P 500 (26W)-45.23%
Price vs S&P 500 (4W)1.54%
Market Capitalization$684.29M
All Metrics
Book Value / Share (Quarterly)$0.67
P/TBV (Annual)2.14x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-16.96%
Cash Flow / Share (Quarterly)$-0.93
Price vs S&P 500 (YTD)6.58%
Net Profit Margin (TTM)-4342.44%
EPS (TTM)$-1.38
10-Day Avg Trading Volume1.87M
EPS Excl Extra (TTM)$-1.38
EPS (Annual)$-1.35
ROI (Annual)-166.41%
Cash / Share (Quarterly)$0.98
Revenue Growth QoQ (YoY)-61.61%
ROA (Last FY)-58.69%
Revenue Growth TTM (YoY)55.28%
EBITD / Share (TTM)$-1.34
ROE (5Y Avg)-110.15%
Operating Margin (TTM)-4498.06%
Cash Flow / Share (Annual)$-0.93
P/B Ratio5.66x
P/B Ratio (Quarterly)5.18x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)134.12x
Net Interest Coverage (TTM)-82.30x
ROA (TTM)-60.27%
EPS Incl Extra (Annual)$-1.35
Current Ratio (Annual)4.84x
Quick Ratio (Quarterly)4.76x
3-Month Avg Trading Volume3.04M
52-Week Price Return184.96%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.99
P/S Ratio (Annual)147.73x
Asset Turnover (Annual)0.01x
52-Week High$6.94
EPS Excl Extra (Annual)$-1.35
CapEx CAGR (5Y)47.91%
26-Week Price Return-41.24%
Quick Ratio (Annual)4.76x
13-Week Price Return-11.45%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.84x
Enterprise Value$621.261
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4342.44%
Cash / Share (Annual)$0.98
3-Month Return Std Dev83.56%
Net Income / Employee (TTM)$-1
ROE (Last FY)-166.41%
Net Interest Coverage (Annual)-25.03x
EPS Basic Excl Extra (Annual)$-1.35
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.38
ROI (TTM)-178.61%
P/S Ratio (TTM)147.73x
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$3.25
Price vs S&P 500 (52W)155.13%
Year-to-Date Return9.22%
5-Day Price Return7.98%
EPS Normalized (Annual)$-1.35
ROA (5Y Avg)-63.07%
Net Profit Margin (Annual)-4342.44%
Month-to-Date Return8.91%
Cash Flow / Share (TTM)$-1.79
EBITD / Share (Annual)$-1.35
Operating Margin (Annual)-4498.06%
ROI (5Y Avg)-110.15%
EPS Basic Excl Extra (TTM)$-1.38
P/TBV (Quarterly)3.49x
P/B Ratio (Annual)5.18x
Pretax Margin (TTM)-4342.44%
Book Value / Share (Annual)$0.67
Price vs S&P 500 (13W)-12.14%
Beta2.58x
Revenue / Share (TTM)$0.03
ROE (TTM)-178.61%
52-Week Low$1.11
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.05
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PRMEPrime Medicine, Inc. Common Stock | 147.73x | 55.28% | — | — | $3.67 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Prime Medicine Inc develops genetic therapies based on Prime Editing, a next-generation gene-editing technology designed to precisely correct genetic mutations and restore normal cellular function. The company targets rare and severe diseases with significant unmet medical needs across multiple therapeutic areas. Prime Editing's broader applicability compared to earlier gene-editing approaches positions the company to address a substantial market opportunity.